You just read:

Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome

News provided by

Aprea Therapeutics AB

May 23, 2017, 08:00 ET